

## Key highlights of data accepted by ESC

Asset / Program	Title	Location & Format	Date & Time (CEST)
<b>Pelacarsen</b>	Pelacarsen reduces the need for lipoprotein apheresis in patients with elevated lipoprotein(a) and cardiovascular disease: The Phase 3 Lp(a)FRONTIERS APHERESIS trial	Station 12 (Research Gateway), Moderated ePoster	August 29, 09:15–10:00
<b>Pelacarsen</b>	Association of elevated lipoprotein(a) with future major adverse cardiovascular events in recurrent ASCVD patients: analysis of a large US electronic health record database	Station 2 (Research Gateway), Moderated ePoster	August 30, 17:15–18:00
<b>Pelacarsen</b>	Economic burden of elevated lipoprotein(a) in secondary prevention of atherosclerotic cardiovascular disease cohort from England	Discovery Pole (North Convention Centre), Poster	August 29, 15:15
<b>Leqvio</b>	VICTORION-Difference study: Inclisiran-based strategy vs standard of care	Madrid (Main Auditorium), Hot Line	August 30, 17:00
<b>Leqvio</b>	VICTORION-Mono China: efficacy and safety of inclisiran as monotherapy in Chinese adults with low or moderate ASCVD risk and elevated LDL-C	Discovery Pole (North Convention Centre), Poster	August 29, 10:00
<b>Abelacimab</b>	Prior anticoagulation experience, bleeding risk, and safety of factor XI inhibition in atrial fibrillation: an analysis of AZALEA-TIMI 71	Science Box 3 (Research Gateway), Poster	September 1, 14:30
<b>Abelacimab</b>	Renal function and factor XI inhibition in atrial fibrillation: a pre-specified analysis of AZALEA-TIMI 71	Science Box 3 (Research Gateway), Poster	September 1, 15:00
<b>Entresto</b>	PARACHUTE-HF: Randomized trial comparing sacubitril/valsartan with enalapril in patients with HFrEF caused by chronic Chagas cardiomyopathy	Madrid (Main Auditorium), Hot Line	September 1, 08:15